| Literature DB >> 26672722 |
Deise Regina Baptista1, Rubia Daniela Thieme2, Walleri Christini Torelli Reis3, Roberto Pontarolo3, Cassyano Januário Correr3.
Abstract
BACKGROUND: Diabetes and its complications are substantial causes of morbidity and mortality, and caused approximately 5.1 million deaths worldwide in 2013. Early detection and treatment of diabetes complications can prevent their progression. OBJECT: This study compared the proportions of patients with type 1 and 2 diabetes mellitus (T1DM and T2DM, respectively) who achieved the goals of good clinical control.Entities:
Keywords: Diabetes care; Goals of good clinical practice; Support network
Year: 2015 PMID: 26672722 PMCID: PMC4678462 DOI: 10.1186/s13098-015-0107-3
Source DB: PubMed Journal: Diabetol Metab Syndr ISSN: 1758-5996 Impact factor: 3.320
Characteristics of type 1 and 2 diabetes mellitus patients
|
| T1DM + T2DMa |
| T1DMa |
| T2DMa |
| |
|---|---|---|---|---|---|---|---|
| Age (years) | 1030 | 57.0 (18–92) | 298 | 31.0 (18–70) | 732 | 62.0 (22–92) | <0.01 |
| Weight (kg) | 1015 | 74.0 (27.0–139.0) | 281 | 66.3 (27.0–128.5) | 706 | 77.4 (38.8–139.0) | <0.01 |
| Height (cm) | 988 | 160.0 (139.0–196.0) | 281 | 164.0 (140.0–196.0) | 706 | 1.59 (139.0–187.0) | <0.01 |
| BMI (kg/m2) | 987 | 28.1 (11.8–54.3) | 281 | 24.3 (11.8–46,1) | 706 | 29.8 (17.7–54.3) | <0.01 |
| Number of clinical visits—DM (last year) | 1030 | 2.0 (0–11) | 298 | 3.0 (0–5) | 732 | 2.0 (0–11) | <0.01 |
| Number of clinical visit—other (last year) | 1031 | 1.0 (0–57) | 299 | 0.0 (0–37) | 732 | 1.0 (0–57) | <0.01 |
| Period of treatment for DM (years) | 1027 | 7.0 (0–30.0) | 297 | 9.0 (0–30.0) | 730 | 6.0 (0–30.0) | <0.01 |
T1DM type 1 diabetes mellitus, T2DM type 2 diabetes mellitus, BMI body mass index
* Mann–Whitney U test
aMedian (range)
Numbers and proportions of type 1 and 2 diabetes mellitus patients who achieved the goals for metabolic control and screening for diabetic complications
| T1DM + T2DM | T1DM | T2DM |
| |||
|---|---|---|---|---|---|---|
|
|
| Goals achieved % ( |
| Goals achieved % ( | ||
| BMI | 1010 | 299 | 52.5 (157) | 711 | 14.9 (106) | 0.00 |
| sBP | 1025 | 296 | 83.4 (247) | 729 | 62.8 (458) | 0.00 |
| dBP | 1025 | 296 | 88.8 (263) | 729 | 82.0 (598) | 0.00 |
| HbA1c | 1004 | 293 | 9.5 (28) | 711 | 33.3 (237) | 0.00 |
| TC | 984 | 287 | 76.3 (219) | 697 | 81.1 (565) | 0.09 |
| HDL | 986 | 288 | 55.6 (160) | 698 | 29.7 (207) | 0.00 |
| LDL | 966 | 281 | 46.2 (130) | 685 | 58.2 (399) | 0.00 |
| TG | 984 | 288 | 84.0 (242) | 696 | 58.0 (404) | 0.00 |
T1DM type 1 diabetes mellitus, T2DM type 2 diabetes mellitus, BMI body mass index, sBP systolic blood pressure, dBP diastolic blood pressure, TC total cholesterol, HDL high-density lipoprotein cholesterol, LDL low-density lipoprotein cholesterol, TG triglycerides
* χ 2 test
Process measurements and outcome measures of patients with type 1 and 2 diabetes mellitus
|
| T1DM + T2DMa |
| T1DMa |
| T2DMa |
| |
|---|---|---|---|---|---|---|---|
| sBP (mmHg) | 1025 | 120 (70–222) | 296 | 120 (70–222) | 729 | 130 (80–220) | 0.00 |
| dBP (mmHg) | 1025 | 80 (40–130) | 296 | 70 (40–121) | 729 | 80 (51–130) | 0.01 |
| HbA1c (%) | 1004 | 8.2 (4.1–16.2) | 299 | 9.0 (4.1–16.2) | 711 | 7.8 (4.3–16.0) | 0.00 |
| TC (mmol/L) | 984 | 4.3 (1.9–9.1) | 287 | 4.4 (2.6–8.3) | 697 | 4.3 (1.9–9.1) | 0.01 |
| HDL (mmol/L) | 986 | 1.1 (0.4–2.5) | 288 | 1.2 (0.5–2.5) | 698 | 1.0 (0.4–1.5) | 0.00 |
| LDL (mmol/L) | 966 | 2.5 (0.4–6.8) | 281 | 2.6 (1.0–6.7) | 685 | 2.4 (0.4–6.8) | 0.00 |
| TG (mmol/L) | 984 | 1.3 (0.2–9.3) | 288 | 1.0 (0.3–7.9) | 695 | 1.5 (0.2–9.3) | 0.00 |
T1DM type 1 diabetes mellitus, T2DM type 2 diabetes mellitus, dBP diastolic blood pressure, TC total cholesterol, HDL high-density lipoprotein cholesterol, LDL low-density lipoprotein cholesterol, TG triglycerides, sBP systolic blood pressure
* Mann–Whitney U test
aMedian (range)
Frequencies of requests, prescriptions, and educational actions as process measures and outcomes indicators for patients with type 1 and 2 diabetes mellitus
|
| T1DM + T2DM (%) |
| T1DM (%) |
| T2DM (%) |
| |
|---|---|---|---|---|---|---|---|
| Foot examination | 618 | 59.9 | 227 | 75.9 | 391 | 53.4 | 0.00* |
| Funduscopy | 445 | 43.2 | 164 | 54.8 | 451 | 38.4 | 0.00* |
| Microalbuminuria | 942 | 91.4 | 266 | 89.0 | 676 | 92.3 | 0,08* |
| Nutritional education | 457 | 44.3 | 109 | 36.5 | 348 | 47.5 | 0.00* |
| Physical education | 266 | 25.8 | 60 | 20.1 | 206 | 28.1 | 0.00* |
| Smoking cessation education | 14 | 1.4 | 4 | 1.3 | 10 | 1.4 | 1.00** |
| Glucose self-monitoring | 637 | 61.8 | 247 | 82.6 | 390 | 53.3 | 0.00* |
| ACE or ARA2 inhibitor prescription | 677 | 65.66 | 123 | 41.13 | 554 | 75.7 | 0.00** |
| Aspirin prescription | 525 | 50.9 | 60 | 20.1 | 465 | 63.5 | 0.00* |
T1DM type 1 diabetes mellitus, T2DM type 2 diabetes mellitus, ACE angiotensin-converting enzyme
* χ 2 test
** Fisher’s exact test
Supporting process measures of patients with type 1 and 2 diabetes mellitus
|
| T1DM + T2DM (%) |
| T1DM (%) |
| T2DM (%) |
| |
|---|---|---|---|---|---|---|---|
| Last prescription for DM | |||||||
| Diet | 16 | 1.5 | 0 | 0 | 16 | 2.1 | 0.00* |
| OHA monotherapy | 145 | 14.0 | 0 | 0 | 145 | 19.8 | |
| OHA combination therapy | 120 | 11.7 | 0 | 0 | 120 | 16.3 | |
| Insulin + OHA combination therapy | 383 | 37.1 | 38 | 12.7 | 345 | 47.1 | |
| Insulin monotherapy | 367 | 35.7 | 257 | 86.0 | 110 | 15.0 | |
| Antihyperlipidemic agents | 738 | 71.6 | 132 | 44.1 | 606 | 82.8 | 0.00* |
| Antihypertensive agents | 738 | 71.6 | 131 | 43.8 | 607 | 82.9 | 0.00** |
T1DM type 1 diabetes mellitus, T2DM type 2 diabetes mellitus, OHA oral hypoglycemic agent, ARA2 angiotensin II receptor antagonist
* χ 2 test
** Fisher’s exact test